TY - JOUR
T1 - Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?
AU - Principe, Nicola
AU - Kidman, Joel
AU - Lake, Richard A.
AU - Lesterhuis, Willem Joost
AU - Nowak, Anna K.
AU - McDonnell, Alison M.
AU - Chee, Jonathan
PY - 2021/4/27
Y1 - 2021/4/27
N2 - The success of immunotherapy that targets inhibitory T cell receptors for the treatment of multiple cancers has seen the anti-tumor immune response re-emerge as a promising biomarker of response to therapy. Longitudinal characterization of T cells in the tumor microenvironment (TME) helps us understand how to promote effective anti-tumor immunity. However, serial analyses at the tumor site are rarely feasible in clinical practice. Malignant pleural effusions (MPE) associated with thoracic cancers are an abnormal accumulation of fluid in the pleural space that is routinely drained for patient symptom control. This fluid contains tumor cells and immune cells, including lymphocytes, macrophages and dendritic cells, providing a window into the local tumor microenvironment. Recurrent MPE is common, and provides an opportunity for longitudinal analysis of the tumor site in a clinical setting. Here, we review the phenotype of MPE-derived T cells, comparing them to tumor and blood T cells. We discuss the benefits and limitations of their use as potential dynamic biomarkers of response to therapy.
AB - The success of immunotherapy that targets inhibitory T cell receptors for the treatment of multiple cancers has seen the anti-tumor immune response re-emerge as a promising biomarker of response to therapy. Longitudinal characterization of T cells in the tumor microenvironment (TME) helps us understand how to promote effective anti-tumor immunity. However, serial analyses at the tumor site are rarely feasible in clinical practice. Malignant pleural effusions (MPE) associated with thoracic cancers are an abnormal accumulation of fluid in the pleural space that is routinely drained for patient symptom control. This fluid contains tumor cells and immune cells, including lymphocytes, macrophages and dendritic cells, providing a window into the local tumor microenvironment. Recurrent MPE is common, and provides an opportunity for longitudinal analysis of the tumor site in a clinical setting. Here, we review the phenotype of MPE-derived T cells, comparing them to tumor and blood T cells. We discuss the benefits and limitations of their use as potential dynamic biomarkers of response to therapy.
KW - checkpoint receptors
KW - immune checkpoint therapy
KW - malignant pleural effusions (MPE)
KW - memory T cells
KW - T cells
UR - http://www.scopus.com/inward/record.url?scp=85105643650&partnerID=8YFLogxK
U2 - 10.3389/fonc.2021.672747
DO - 10.3389/fonc.2021.672747
M3 - Review article
C2 - 33987104
AN - SCOPUS:85105643650
VL - 11
JO - Frontiers in Oncology
JF - Frontiers in Oncology
SN - 2234-943X
M1 - 672747
ER -